182 related articles for article (PubMed ID: 17021819)
1. Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site.
Sève P; Reiman T; Lai R; Hanson J; Santos C; Johnson L; Dabbagh L; Sawyer M; Dumontet C; Mackey JR
Cancer Chemother Pharmacol; 2007 Jun; 60(1):27-34. PubMed ID: 17021819
[TBL] [Abstract][Full Text] [Related]
2. Protein abundance of class III beta-tubulin but not Delta2-alpha-tubulin or tau is related to paclitaxel response in carcinomas of unknown primary site.
Sève P; Reiman T; Isaac S; Trillet-Lenoir V; Lafanéchère L; Sawyer M; Dumontet C
Anticancer Res; 2008; 28(2B):1161-7. PubMed ID: 18505052
[TBL] [Abstract][Full Text] [Related]
3. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy.
Sève P; Isaac S; Trédan O; Souquet PJ; Pachéco Y; Pérol M; Lafanéchère L; Penet A; Peiller EL; Dumontet C
Clin Cancer Res; 2005 Aug; 11(15):5481-6. PubMed ID: 16061864
[TBL] [Abstract][Full Text] [Related]
4. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel.
Azuma K; Sasada T; Kawahara A; Takamori S; Hattori S; Ikeda J; Itoh K; Yamada A; Kage M; Kuwano M; Aizawa H
Lung Cancer; 2009 Jun; 64(3):326-33. PubMed ID: 18977553
[TBL] [Abstract][Full Text] [Related]
5. The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.
Leskelä S; Leandro-García LJ; Mendiola M; Barriuso J; Inglada-Pérez L; Muñoz I; Martínez-Delgado B; Redondo A; de Santiago J; Robledo M; Hardisson D; Rodríguez-Antona C
Endocr Relat Cancer; 2011 Feb; 18(1):85-95. PubMed ID: 21051560
[TBL] [Abstract][Full Text] [Related]
6. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III beta-tubulin.
Umezu T; Shibata K; Kajiyama H; Terauchi M; Ino K; Nawa A; Kikkawa F
Int J Gynecol Pathol; 2008 Apr; 27(2):207-12. PubMed ID: 18317222
[TBL] [Abstract][Full Text] [Related]
7. Association between class III β-tubulin expression and response to paclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: a meta-analysis.
Zhang HL; Ruan L; Zheng LM; Whyte D; Tzeng CM; Zhou XW
Lung Cancer; 2012 Jul; 77(1):9-15. PubMed ID: 22306125
[TBL] [Abstract][Full Text] [Related]
8. [Class III beta tubulin expression in nonsmall cell lung cancer].
Sève P; Dumontet C
Rev Mal Respir; 2010 Apr; 27(4):383-6. PubMed ID: 20403547
[TBL] [Abstract][Full Text] [Related]
9. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer.
Okuda K; Sasaki H; Dumontet C; Kawano O; Yukiue H; Yokoyama T; Yano M; Fujii Y
Lung Cancer; 2008 Oct; 62(1):105-12. PubMed ID: 18395930
[TBL] [Abstract][Full Text] [Related]
10. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
[TBL] [Abstract][Full Text] [Related]
11. Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance.
Hetland TE; Hellesylt E; Flørenes VA; Tropé C; Davidson B; Kærn J
Hum Pathol; 2011 Jul; 42(7):1019-26. PubMed ID: 21315408
[TBL] [Abstract][Full Text] [Related]
12. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.
Mozzetti S; Ferlini C; Concolino P; Filippetti F; Raspaglio G; Prislei S; Gallo D; Martinelli E; Ranelletti FO; Ferrandina G; Scambia G
Clin Cancer Res; 2005 Jan; 11(1):298-305. PubMed ID: 15671559
[TBL] [Abstract][Full Text] [Related]
13. Expression of class III beta tubulin in cervical cancer patients administered preoperative radiochemotherapy: correlation with response to treatment and clinical outcome.
Ferrandina G; Martinelli E; Zannoni GF; Distefano M; Paglia A; Ferlini C; Scambia G
Gynecol Oncol; 2007 Feb; 104(2):326-30. PubMed ID: 17030352
[TBL] [Abstract][Full Text] [Related]
14. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
[TBL] [Abstract][Full Text] [Related]
15. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10.
Sève P; Lai R; Ding K; Winton T; Butts C; Mackey J; Dumontet C; Dabbagh L; Aviel-Ronen S; Seymour L; Whitehead M; Tsao MS; Shepherd FA; Reiman T
Clin Cancer Res; 2007 Feb; 13(3):994-9. PubMed ID: 17289895
[TBL] [Abstract][Full Text] [Related]
16. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.
Ferrandina G; Zannoni GF; Martinelli E; Paglia A; Gallotta V; Mozzetti S; Scambia G; Ferlini C
Clin Cancer Res; 2006 May; 12(9):2774-9. PubMed ID: 16675570
[TBL] [Abstract][Full Text] [Related]
17. The evolving role of paclitaxel for patients with carcinoma of unknown primary site.
Greco FA; Hainsworth JD
Semin Oncol; 1999 Feb; 26(1 Suppl 2):129-33. PubMed ID: 10190795
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival.
Alberts DS; Marth C; Alvarez RD; Johnson G; Bidzinski M; Kardatzke DR; Bradford WZ; Loutit J; Kirn DH; Clouser MC; Markman M;
Gynecol Oncol; 2008 May; 109(2):174-81. PubMed ID: 18314182
[TBL] [Abstract][Full Text] [Related]
19. Class III β-tubulin overexpression in ovarian clear cell and serous carcinoma as a maker for poor overall survival after platinum/taxane chemotherapy and sensitivity to patupilone.
Roque DM; Bellone S; Buza N; Romani C; Cocco E; Bignotti E; Ravaggi A; Rutherford TJ; Schwartz PE; Pecorelli S; Santin AD
Am J Obstet Gynecol; 2013 Jul; 209(1):62.e1-9. PubMed ID: 23583215
[TBL] [Abstract][Full Text] [Related]
20. Human breast cancer susceptibility to paclitaxel therapy is independent of Bcl-2 expression.
Poelman SM; Adeyanju MO; Robertson MA; Recant WM; Karrison T; Fleming GF; Olopade OI; Conzen SD
Clin Cancer Res; 2000 Oct; 6(10):4043-8. PubMed ID: 11051254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
